Inspire Medical Systems, Inc. to Report First Quarter 2022 Financial Results on May 3, 2022
Inspire Medical Systems, Inc. (NYSE: INSP) will release its first-quarter 2022 financial results on May 3, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Inspire Medical Systems, Inc. (NYSE: INSP) will release its first-quarter 2022 financial results on May 3, after market close. Management will host a conference call at 5:00 p.m. ET to discuss these results and recent developments. Inspire specializes in innovative, minimally invasive solutions for obstructive sleep apnea, showcasing its FDA-approved neurostimulation technology as a leading treatment option. For further details, visit Inspire's website.
Positive
- Inspire has FDA approval for its proprietary neurostimulation therapy, enhancing its market position.
Negative
- No specific financial metrics or guidance provided, leaving uncertainty about performance.
Details
News Market Reaction – INSP
The recorded move for INSP in the trading session of this news was -0.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, April 05, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the first quarter 2022 after the close of trading on Tuesday, May 3. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
| Tuesday, May 3rd @ 5:00 p.m. Eastern Time: | |
| Domestic: | (800) 344-0786 |
| International: | (209) 905-5969 |
| Conference ID: | 5029338 |
| Webcast: | https://edge.media-server.com/mmc/p/inp4vfpu |
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.